© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to January
p300/CBP bromodomain inhibitor
PD observed in serial biopsies from Ph. I
50 mg QD, 3-d-on-4-off; origin not discussed
Cancer Discovery, Jan. 11, 2021
ICR / Royal Marsden / CellCentric, UK
The CellCentric p300/CBP inhibitor, CCS1477, is an orally available drug in early development for advanced prostate cancer, and is structurally distinct from the p300/CBP inhibitor we covered in Apr.…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.